High expression of p63 is correlated to poor prognosis in squamous cell carcinoma of the tongue

Journal of Oral Pathology and Medicine

Volumn 43, Issue 1, 2014, Pages 14-19

  Loljung, Lotta ^a   Coates, Philip J ^b   Nekulova, Marta ^c   Laurell, Göran ^a,d   Wahlgren, Magnus ^a   Wilms, Torben ^a   Widlöf, Mikael ^a   Hansel, Anna ^a   Nylander, Karin ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

P63; Prognosis; Tongue carcinoma

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN P63; ISOPROTEIN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL TIME; TONGUE CARCINOMA; VERY ELDERLY; YOUNG ADULT; ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SURVIVAL RATE; TONGUE NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEIN ISOFORMS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TONGUE NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84891834767     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12074     Document Type: Article

References (32)

1. Boldrup L, Coates PJ, Laurell G, Nylander K. Differences in p63 expression in SCCHN tumours of different sub-sites within the oral cavity. Oral Oncol 2011; 47: 861-5.
2. Bockmühl U, Schwendel A, Dietel M, Petersen I. Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res 1996; 56: 5325-9.
3. Lundqvist L, Stenlund H, Laurell G, Nylander K. The importance of stromal inflammation in squamous cell carcinoma of the tongue. J Oral Pathol Med 2012; 41: 379-83.
4. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-16.
5. Koster MI, Roop DR. The role of p63 in development and differentiation of the epidermis. J Dermatol Sci 2004; 34: 3-9.
6. Thurfjell N, Coates PJ, Uusitalo T, et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004; 25: 27-35.
7. Vigano MA, Vigana MA, Lamartine J, et al. New p63 targets in keratinocytes identified by a genome wide approach. EMBO J 2006; 25: 1-12.
8. Gu X, Coates PJ, MacCallum SF, Boldrup L, Sjöström B, Nylander K. TRAF4 is potently induced by TAp63 isoforms and localised according to differentiation in SCCHN. Cancer Biol Ther 2007; 6: 1986-90.
9. Gu X, Coates PJ, Boldrup L, Nylander K. p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. Cancer Lett 2008; 263: 26-34.
10. Boldrup L, Coates PJ, Gu X, Nylander K. {increment}Np63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol 2007; 213: 384-91.
11. Boldrup L, Coates PJ, Gu X, Nylander K. {increment}Np63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target. J Pathol 2009; 218: 428-36.
12. Boldrup L, Coates PJ, Laurell G, Nylander K. P63 transcriptionally regulates BNC1, a pol I and pol II transcription factor that regulates ribosomal biogenesis and epithelial differentiation. Eur J Cancer 2012; 48: 1401-6.
13. Tseng H, Green H. Association of basonuclin with ability of keratinocytes to multiply and with absence of terminal differentiation. J Cell Biol 1994; 126: 495-506.
14. Thurfjell N, Coates PJ, Vojtesek B, Benham-Motlagh P, Eisold M, Nylander K. Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int J Mol Med 2005; 16: 1065-70.
15. Lo Muzio L, Santarelli A, Caltabiano R, et al. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 2005; 36: 187-94.
16. Moergel M, Abt E, Stockinger M, Kunkel M. Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma. Oral Oncol 2010; 46: 667-71.
17. Foschini MP, Gaiba A, Cocchi R, et al. Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch 2004; 444: 332-9.
18. Oliveira LR, Ribeiro-Silva A, Zucoloto S. Prognostic significance of p53 and p63 immunolocalisation in primary and matched lymph node metastasis in oral squamous cell carcinoma. Acta Histochem 2007; 109: 388-96.
19. de Oliveira LR, Ribeiro-Silva A, Zucoloto S. Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J Oral Pathol Med 2007; 36: 191-7.
20. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-80.
21. Detre S, Saccani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48: 876-8.
22. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002; 198: 417-27.
23. Nekulova M, Holcakova J, Nenutil R, et al. Immunohistochemical identification of p63 and TAp63 versus {increment}Np63 in normal tissues and cervical squamous cancers: implications for p63 function. Submitted February 2013.
24. Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA. Evaluation of p63 and p73 antibodies for cross-reactivity. Cell Cycle 2009; 8: 3702-6.
25. Faridoni-Laurens L, Bosq J, Janto F, et al. p73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 2001; 20: 5302-12.
26. Guo X, Keyes WM, Papazoglu C, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 2009; 11: 1451-8.
27. Koster MI, Lu SL, White LD, Wang XJ, Roop DR. Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. Cancer Res 2006; 66: 3981-6.
28. Vered M, Allon I, Dayan D. Maspin, p53, p63, and Ki-67 in epithelial lesions of the tongue: from hyperplasia through dysplasia to carcinoma. J Oral Pathol Med 2009; 38: 314-20.
29. Lo Muzio L, Campisi G, Farina A, et al. Effect of p63 expression on survival in oral squamous cell carcinoma. Cancer Invest 2007; 25: 464-9.
30. Borba M, Cernea C, Dias F, et al. Expression profile of p63 in 127 patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2010; 72: 319-24.
31. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 2010; 5: 349-71.
32. Uramoto H, Sugio K, Oyqma T, et al. Expression of the p53 family in lung cancer. Anticancer Res 2006; 26: 1785-90.